Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) announced it has regained compliance with the Nasdaq minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq confirmed on December 30, 2025 that the company’s common shares closed at $1.00 or greater for 10 consecutive business days from December 15 through December 29, 2025.

The company had previously received a notice of noncompliance dated December 4, 2025 after the closing bid price remained below $1.00 for more than 30 consecutive business days. Nasdaq indicated the matter is now closed.

Positive

• Regained compliance with Rule 5550(a)(2) on Dec 30, 2025
• 10 consecutive business days with closing bid ≥ $1.00 (Dec 15–29, 2025)
• Nasdaq confirmed the matter is closed

Negative

• Notified of noncompliance after >30 business days below $1.00
• Nasdaq noncompliance notice received on Dec 4, 2025

Key Figures

Minimum bid threshold $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement met Dec 15–29, 2025

Non-compliance period 30+ business days Closing bid below $1.00 before Dec 4, 2025 Nasdaq notice

Compliance window 10 consecutive business days Closing bid at or above $1.00 from Dec 15–29, 2025

Current share price $1.86 Pre-news close vs 52-week range $1.85–$70.00

Market Reality Check

$1.99 Last Close

Volume Volume 71,421 is well below 20-day average of 402,406, indicating muted trading interest before this update. low

Technical Shares at $1.86 are far below the $33.76 200-day MA and just above the $1.85 52-week low, despite the compliance news.

Peers on Argus 1 Down

Peer biotech names show mixed moves: some down (e.g., SXTP -8.57%, TTNP -3.96%) and others up (PLRZ +3.33%, SILO +2.64%), suggesting CMND’s setup was stock-specific rather than a broad sector trend.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 24	Year-in-review update	Positive	-5.8%	Highlighted 2025 clinical and IP advances for lead candidate CMND-100.
Dec 16	Clinical trial progress	Positive	-3.7%	Announced completion of second cohort enrollment in Phase I/IIa AUD trial.
Dec 12	Scientific review highlight	Positive	+3.6%	Peer-reviewed article spotlighted MEAI/CMND-100’s potential and safety profile.
Dec 12	Nasdaq equity compliance	Positive	+3.6%	Regained compliance with Nasdaq minimum stockholders’ equity requirement.
Dec 10	Reverse share split	Neutral	-6.1%	Announced 1-for-40 reverse split to address Nasdaq minimum bid price rule.

Pattern Detected

Recent positive clinical and compliance news often saw mixed reactions, with some selloffs on broadly constructive updates and gains on Nasdaq compliance milestones.

Recent Company History

Over the past months, Clearmind reported multiple milestones, including a 1-for-40 reverse split to support Nasdaq bid compliance, regaining compliance with the $2,500,000 stockholders’ equity rule, and continued progress in its Phase I/IIa CMND-100 trial. Some positive clinical and scientific updates coincided with price declines, while regulatory compliance announcements produced gains. Today’s confirmation of regaining the minimum bid price requirement extends this sequence of Nasdaq-related compliance developments.

Market Pulse Summary

This announcement confirms CMND has regained compliance with Nasdaq’s minimum bid price rule by maintaining a closing bid of at least $1.00 for 10 consecutive business days. It follows earlier steps to address listing standards, including a 1-for-40 reverse split and regained stockholders’ equity compliance. Investors may focus on whether the company can sustain both its listing compliance and clinical progress, given its position near the $1.85 52-week low and well below the $33.76 200-day moving average.

Key Terms

nasdaq stock market financial

"notification letter from the Listing Qualifications Department of the Nasdaq Stock Market"

The Nasdaq Stock Market is a place where many companies' shares are bought and sold, functioning like a marketplace for investing in businesses. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping people grow their wealth or fund business growth. Known for hosting many technology and innovative companies, it is a key indicator of the health of those sectors.

minimum bid price financial

"regained compliance with the minimum bid price requirement set forth"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

closing bid price financial

"the closing bid price of the Company’s common shares had been below $1.00"

The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.

listing qualifications department regulatory

"notification letter from the Listing Qualifications Department of the Nasdaq Stock Market"

A listing qualifications department is the part of a stock exchange that checks whether a company meets the exchange’s rules for being listed and staying listed. Think of it as a gatekeeper or building inspector: it reviews financial statements, disclosure practices and corporate governance, flags problems and can require fixes or remove a company’s shares. Investors care because its decisions affect whether a stock remains tradable and how much trust to place in a company’s reporting.

AI-generated analysis. Not financial advice.

Vancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

The Company had previously announced that it was notified by Nasdaq on December 4, 2025, that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s common shares had been below $1.00 for more than 30 consecutive business days.

On December 30, 2025, Nasdaq provided confirmation to the Company that for the last 10 consecutive business days, from December 15 through December 29, 2025, the closing bid price of the Company’s common shares was $1.00 per share or greater, that the Company has hence regained compliance with Listing Rule 5550(a)(2) and that the matter is now closed.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses advancing innovative treatments for AUD, the high level of interest from both patients and leading clinical sites in CMND-100, CMND-100’s potential to transform AUD treatment and its belief that that this rapid progress positions it to generate additional valuable data, bringing it closer to delivering a breakthrough therapy that addresses the root causes of addiction with an improved safety profile. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What did Clearmind (CMND) announce about Nasdaq compliance on December 31, 2025?

Clearmind said it regained compliance with Nasdaq Listing Rule 5550(a)(2) after Nasdaq confirmed compliance on Dec 30, 2025.

How did Clearmind (CMND) regain Nasdaq compliance in December 2025?

The company’s shares closed at $1.00 or greater for 10 consecutive business days from Dec 15–29, 2025.

When did Nasdaq confirm Clearmind (CMND) was back in compliance?

Nasdaq provided confirmation to Clearmind on Dec 30, 2025 that the company regained compliance.

What triggered the earlier Nasdaq noncompliance notice for CMND?

A notice of noncompliance dated Dec 4, 2025 followed the share closing bid being below $1.00 for more than 30 consecutive business days.

Does the December 30, 2025 Nasdaq notice affect CMND’s listing status?

Yes; Nasdaq confirmed the company regained compliance and stated the matter is closed.

What period satisfied Nasdaq’s minimum bid price requirement for CMND?

The satisfying period was 10 consecutive business days from Dec 15 through Dec 29, 2025 with closing bids ≥ $1.00.